More News
14 January 2014
Amarantus In-Licenses Levadopa-Induced Dyskinesia Phase 2b-Ready Eltoprazine From PGI Drug Discovery13 January 2014
Galena Biopharma Acquires Mills Pharmaceuticals, LLC13 January 2014
Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines12 January 2014
Nuevolution Announces Technology Licensing Agreement12 January 2014
InteRNA Technologies, UCB and University of Bonn to Collaborate on the Role of MicroRNAs in Neurodegenerative Disease10 January 2014
Santaris Pharma A/S announce agreement with GlaxoSmithKline (GSK) to develop RNA-targeted medicines10 January 2014
AC Immune raises CHF 20 million and initiates world’s first anti-pTau vaccine trial for Alzheimer’s disease9 January 2014
Santaris A/S announces worldwide discovery alliance for RNA-targeted medicines with Roche9 January 2014
Zymeworks Announces $15.0 Million Private Placement Financing to Advance Lead Programs into Clinical Trials9 January 2014
Five Prime Therapeutics Enters Into Antibody Research Collaboration Agreement With Adimab9 January 2014
Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies9 January 2014
Sunesis Pharmaceuticals Expands Hematology Franchise With Global Licenses to Two Kinase Inhibitor Programs9 January 2014
Teva Names Erez Vigodman as President and CEONews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports